Optimization and Validation of a Harmonized Protocol for Generating Therapeutic-Grade Dendritic Cells in a Randomized Phase II Clinical Trial, Using Two Varied Antigenic Sources.

Vaccines (Basel) · 2024 · PMC10892253 · PMID 38400096

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Phenotypic Expression of Batch-Produced DCs The phenotypic expression analysis showed that, consistently, in all the MDCs, (irrespective of the antigenic priming source), the expression of maturation marker CD83 showed an average six-fold increase, which was found to be highly significant (IDC vs.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.